{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:45:02Z","timestamp":1791953102841,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01058-z","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:00:31Z","timestamp":1791925231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protecting Trial Integrity Through Monitoring and Analysis of Medication Adherence"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-1253","authenticated-orcid":false,"given":"Bernard","family":"Vrijens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Binkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Goetghebeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"C. Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhi","family":"Kilaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrick","family":"Wallstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1058_CR1","unstructured":"International Council for Harmonisation. Guideline for Good Clinical Practice E6(R3). ICH; 2025."},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/jcph.689","volume":"56","author":"TM Shiovitz","year":"2016","unstructured":"Shiovitz TM, Bain EE, McCann DJ, et al. Mitigating the Effects of Nonadherence in Clinical Trials. J Clin Pharmacol. 2016;56:1151\u201364.","journal-title":"J Clin Pharmacol"},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrd.2017.1","volume":"16","author":"A Breckenridge","year":"2017","unstructured":"Breckenridge A, Aronson JK, Blaschke TF, et al. Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov. 2017;16:149\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/europace\/euu311","volume":"17","author":"B Vrijens","year":"2015","unstructured":"Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17:514\u201323.","journal-title":"Europace"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/cpdd.1022","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X, Raoufinia A, Bihorel S, et al. Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. Clin Pharmacol Drug Dev. 2022;11:150\u201364.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10:e332\u201342.","journal-title":"Lancet HIV"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","volume":"52","author":"TF Blaschke","year":"2012","unstructured":"Blaschke TF, Osterberg L, Vrijens B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275\u2013301.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/clpt.2010.171","volume":"88","author":"LG Osterberg","year":"2010","unstructured":"Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88:457\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1058_CR10","first-page":"9","volume":"38","author":"B Vrijens","year":"2024","unstructured":"Vrijens B, Pironet A, Tousset E. The Importance of Assessing Drug Exposure and Medication Adherence in Evaluating Investigational Medications: Ensuring Validity and Reliability of Clinical Trial Results. Pharmaceut Med. 2024;38:9\u201318.","journal-title":"Pharmaceut Med"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1310\/hct0904-238","volume":"9","author":"TJ Podsadecki","year":"2008","unstructured":"Podsadecki TJ, Vrijens BC, Tousset EP, et al. White coat compliance limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9:238\u201346.","journal-title":"HIV Clin Trials"},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/JCP.0000000000000372","volume":"35","author":"DJ McCann","year":"2015","unstructured":"McCann DJ, Petry NM, Bresell A, et al. Medication Nonadherence, Professional Subjects, and Apparent Placebo Responders: Overlapping Challenges for Medications Development. J Clin Psychopharmacol. 2015;35:566\u201373.","journal-title":"J Clin Psychopharmacol"},{"key":"1058_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593\u2013603.","journal-title":"Eur J Prev Cardiol"},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, et al. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. N Engl J Med. 2017;376:1690\u20132.","journal-title":"N Engl J Med"},{"key":"1058_CR15","unstructured":"Clinical Data Interchange Standards Consortium (CDISC). SDTM ADaM Pilot Project. CDISC; 2008."},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1111\/bcp.14659","volume":"87","author":"AL Dima","year":"2021","unstructured":"Dima AL, Allemann SS, Dunbar-Jacob J, et al. TEOS: A framework for constructing operational definitions of medication adherence based on Timelines-Events-Objectives-Sources. Br J Clin Pharmacol. 2021;87:2521\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s43441-022-00496-9","volume":"57","author":"A Adams","year":"2023","unstructured":"Adams A, Adelfio A, Barnes B, et al. Risk-Based Monitoring in Clinical Trials: 2021 Update. Ther Innov Regul Sci. 2023;57:529\u201337.","journal-title":"Ther Innov Regul Sci"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/17407745221084127","volume":"19","author":"EN Grayek","year":"2022","unstructured":"Grayek EN, Fischhoff B, Davis AL, et al. The value of adherence information during clinical pharmaceutical trials. Clin Trials. 2022;19:326\u201336.","journal-title":"Clin Trials"},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/clpt.2014.59","volume":"95","author":"B Vrijens","year":"2014","unstructured":"Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther. 2014;95:617\u201326.","journal-title":"Clin Pharmacol Ther"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"e052656","DOI":"10.1136\/bmjopen-2021-052656","volume":"12","author":"M Dodd","year":"2022","unstructured":"Dodd M, Fielding K, Carpenter JR, et al. Statistical methods for non-adherence in non-inferiority trials: useful and used? A systematic review. BMJ Open. 2022;12:e052656.","journal-title":"BMJ Open"},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/cts.12910","volume":"14","author":"MF Dockendorf","year":"2021","unstructured":"Dockendorf MF, Hansen BJ, Bateman KP, et al. Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm. Clin Transl Sci. 2021;14:445\u201359.","journal-title":"Clin Transl Sci"},{"key":"1058_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bcp.14240","volume":"86","author":"L Eliasson","year":"2020","unstructured":"Eliasson L, Clifford S, Mulick A, et al. How the EMERGE guideline on medication adherence can improve the quality of clinical trials. Br J Clin Pharmacol. 2020;86:687\u201397.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR23","unstructured":"International Council for Harmonisation. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials (ICH E9[R1]). ICH; 2019."},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1002\/sim.8741","volume":"39","author":"E Goetghebeur","year":"2020","unstructured":"Goetghebeur E, le Cessie S, De Stavola B, et al. Formulating causal questions and principled statistical answers. Stat Med. 2020;39:4922\u201348.","journal-title":"Stat Med"},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","volume":"22","author":"G Danaei","year":"2013","unstructured":"Danaei G, Rodr\u00edguez L, Cantero O, et al. Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22:70\u201396.","journal-title":"Stat Methods Med Res"},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"106778","DOI":"10.1016\/j.ypmed.2021.106778","volume":"153","author":"P Pinsky","year":"2021","unstructured":"Pinsky P, Goodman P, Parnes H, et al. Adherence with protocol medication use and mortality from unrelated causes in a prevention trial. Prev Med. 2021;153:106778.","journal-title":"Prev Med"},{"key":"1058_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/sim.9969","volume":"43","author":"EE Gabriel","year":"2024","unstructured":"Gabriel EE, Sachs MC, Martinussen T, et al. Inverse probability of treatment weighting with generalized linear outcome models for doubly robust estimation. Stat Med. 2024;43:534\u201347.","journal-title":"Stat Med"},{"key":"1058_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/sim.5686","volume":"32","author":"R Daniel","year":"2013","unstructured":"Daniel R, Cousens S, De Stavola B, et al. Methods for dealing with time-dependent confounding. Stat Med. 2013;32:1584\u2013618.","journal-title":"Stat Med"},{"key":"1058_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jclinepi.2018.12.002","volume":"108","author":"M Mostazir","year":"2019","unstructured":"Mostazir M, Taylor R, Henley W, et al. An overview of statistical methods for handling nonadherence to intervention protocol in randomized control trials: a methodological review. J Clin Epidemiol. 2019;108:121\u201331.","journal-title":"J Clin Epidemiol"},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"M Hernan","year":"2016","unstructured":"Hernan M, Robins J. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"1058_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pst.2054","volume":"20","author":"Y Qu","year":"2021","unstructured":"Qu Y, Luo J, Ruberg S. Implementation of Tripartite Estimands using Adherence Causal Estimators under the Causal Inference Framework. Pharm Stat. 2021;20:55\u201367.","journal-title":"Pharm Stat"},{"key":"1058_CR32","unstructured":"European Medicines Agency. ICH E9 statistical principles for clinical trials. EMA; 1998."},{"key":"1058_CR33","unstructured":"European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials. EMA; 2015."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01058-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01058-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01058-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:49:33Z","timestamp":1791949773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01058-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":33,"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01058-z","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Aardex Group","order":1,"name":"Ethics","label":"Vrijens, Bernard","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thermo Fisher Scientific","order":2,"name":"Ethics","label":"Kilaru, Rakhi","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JMP Statistical Discovery LLC","order":3,"name":"Ethics","label":"Zink, Richard C","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arcutis Biotherapeutics Inc","order":4,"name":"Ethics","label":"Binkowitz, Bruce","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ghent University, Mathematics and Computer Science","order":5,"name":"Ethics","label":"Goetghebeur, Els","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thermo Fisher Scientific","order":6,"name":"Ethics","label":"Wallstrom, Garrick","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}